1. A 54-year-old man with hypertension, type 2 diabetes, and pulmonary tuberculosis is being treated with losartan 100 mg daily for blood pressure control and renoprotection. His infectious disease team initiates rifampin as part of a multi-drug antitubercular regimen. Four weeks later, his home blood pressure log shows readings consistently above 155/95 mmHg despite full adherence. Renal function and electrolytes are unchanged. Which of the following best explains the loss of blood pressure control and identifies the most appropriate pharmacological management?
A) Rifampin induces renal tubular secretion of losartan, increasing its urinary clearance and reducing systemic exposure to both losartan and its active metabolite, requiring dose escalation of losartan to 150 mg daily to restore adequate AT1 receptor blockade
B) Rifampin inhibits CYP2C9, impairing the hepatic conversion of losartan to EXP3174 and reducing the proportion of pharmacologically active drug available for AT1 receptor binding; the appropriate response is to add a second antihypertensive agent rather than switch ARBs
C) Rifampin is a potent CYP2C9 and CYP3A4 inducer; induction of CYP2C9 accelerates the conversion of EXP3174 to inactive metabolites while simultaneously altering losartan first-pass kinetics, reducing net AT1 receptor blockade; substituting a non-CYP2C9-dependent ARB such as irbesartan, olmesartan, or valsartan eliminates the interaction and restores antihypertensive efficacy
D) Rifampin competitively inhibits the intestinal OATP1B1 transporter responsible for losartan absorption, reducing bioavailability by approximately 50%; the interaction is absorption-based rather than metabolic and does not affect EXP3174 generation from absorbed losartan
E) Rifampin induces aldosterone synthase, increasing aldosterone production and causing sodium retention that overcomes the antihypertensive effect of losartan; the appropriate intervention is to add a mineralocorticoid receptor antagonist rather than change the ARB
ANSWER: C
Rationale:
Option C is correct. Rifampin is one of the most potent inducers of CYP enzymes in clinical use, with particularly strong induction of CYP3A4 and CYP2C9. Losartan is unique among ARBs in requiring CYP2C9-mediated hepatic conversion to its active metabolite EXP3174, which carries approximately 10- to 40-fold greater AT1 receptor affinity than the parent compound. Rifampin-mediated CYP2C9 induction accelerates EXP3174 formation transiently but more importantly accelerates its further oxidative metabolism to inactive products, while also increasing first-pass extraction of losartan itself; the net result across multiple kinetic steps is substantially reduced steady-state EXP3174 exposure and diminished AT1 receptor blockade. Because valsartan, irbesartan, olmesartan, and candesartan do not depend on CYP2C9 for activation or carry the same CYP2C9-mediated metabolic liability, substituting any of these agents for losartan during rifampin therapy eliminates the pharmacokinetic interaction at its source and restores predictable antihypertensive effect without dose escalation of a drug whose active metabolite pharmacokinetics are now unpredictable.
Option A: Option A is incorrect. Rifampin does not induce renal tubular secretion of losartan; its primary pharmacokinetic effect on losartan is through CYP enzyme induction, not renal transporter upregulation. Dose escalation of losartan to 150 mg daily would not reliably restore efficacy because the underlying problem is unpredictable CYP2C9-mediated metabolism of both losartan and EXP3174, not simple underexposure at the standard dose.
Option B: Option B is incorrect. Rifampin is a CYP inducer, not an inhibitor. Inhibition of CYP2C9 (as produced by fluconazole or amiodarone) would impair EXP3174 generation and reduce efficacy — but rifampin produces the opposite enzymatic effect. Adding a second antihypertensive without addressing the underlying pharmacokinetic interaction would leave the patient on a drug whose predictable dose-response relationship has been disrupted.
Option D: Option D is incorrect. While rifampin does affect some drug transporters, the clinically dominant interaction with losartan is CYP enzyme induction, not OATP1B1-mediated absorption inhibition. The described absorption-only mechanism does not account for the observed loss of blood pressure control, and the framing that absorbed losartan would generate EXP3174 normally ignores the CYP2C9 induction effect on EXP3174 elimination.
Option E: Option E is incorrect. Rifampin does not induce aldosterone synthase. Rifampin's antihypertensive drug interactions are pharmacokinetic in origin, mediated through CYP enzyme induction, not through mineralocorticoid pathway upregulation. Adding spironolactone or eplerenone would not address the losartan-rifampin pharmacokinetic interaction.
2. A 61-year-old woman with hypertension, HFrEF (heart failure with reduced ejection fraction; ejection fraction 38%), and type 2 diabetes develops a persistent dry cough six weeks after starting lisinopril. She has no history of angioedema, wheezing, or chronic lung disease, and spirometry is normal. Her cardiologist plans to substitute an ARB. Which of the following most accurately explains why the ARB will not reproduce the cough and what clinical distinction must be maintained when selecting this agent?
A) Lisinopril causes cough by inhibiting ACE (angiotensin-converting enzyme, also called kininase II), which normally degrades bradykinin in the pulmonary vasculature; accumulated bradykinin activates airway sensory C-fibers through B2 receptors, triggering the cough reflex; ARBs block AT1 receptors without inhibiting ACE and therefore do not impair bradykinin degradation, so the cough resolves; the critical selection distinction is that ARBs carry a substantially lower — but not zero — risk of angioedema, and prior ACEi angioedema (not cough) would contraindicate both ARB and ARNI use
B) Lisinopril causes cough through direct irritation of ACE expressed on bronchial epithelial cells; ARBs bypass bronchial ACE entirely because they act at the receptor level in vascular smooth muscle only; the cough is therefore a class effect of all RAAS-blocking agents and will recur at a lower frequency with ARBs
C) Lisinopril causes cough by blocking angiotensin II-mediated suppression of airway mucus secretion; the resulting mucus accumulation stimulates mechanoreceptors in the trachea; ARBs preserve angiotensin II production but block its receptor, providing equivalent RAAS suppression without the mucolytic mechanism that produces cough
D) Lisinopril causes cough through substance P accumulation secondary to ACE inhibition; ARBs prevent substance P accumulation by blocking AT2 receptors, which normally stimulate substance P release from airway C-fibers; this receptor-level distinction explains the class difference in cough incidence
E) Lisinopril causes cough by blocking conversion of angiotensin I to angiotensin II, reducing the vasodilatory stimulus on bronchial smooth muscle and producing reflex bronchoconstriction; ARBs restore AT1-mediated bronchodilation while blocking AT2-mediated bronchoconstriction, resolving the cough through receptor subtype selectivity
ANSWER: A
Rationale:
Option A is correct. ACE inhibitor-induced cough is a class effect mediated by bradykinin accumulation. ACE (kininase II) normally degrades bradykinin in the pulmonary circulation; when ACE is inhibited, bradykinin accumulates and activates B2 receptors on airway sensory C-fibers, lowering the threshold for the cough reflex and triggering the characteristic persistent dry cough. The cough is not caused by the reduction in angiotensin II itself but by the loss of bradykinin clearance. ARBs act downstream at the AT1 receptor and do not inhibit ACE; bradykinin degradation proceeds normally, and the cough resolves when the ACEi is replaced with an ARB. The clinically critical distinction in the management of this patient is between cough (which resolves with ARB substitution and does not contraindicate ARBs) and angioedema (which reflects heightened susceptibility to bradykinin-mediated vascular permeability and contraindicates both ARBs at a lower level and sacubitril-valsartan, because neprilysin inhibition also raises bradykinin). This patient's cough without angioedema makes ARB substitution straightforward.
Option B: Option B is incorrect. ACE inhibitor cough is not caused by direct bronchial epithelial irritation by ACE protein; it is a pharmacodynamic consequence of bradykinin accumulation mediated by ACE inhibition. Additionally, ACEi cough is not a class effect of all RAAS-blocking agents; it is specific to ACE inhibitors. ARBs do not cause cough at rates exceeding placebo in clinical trials, reflecting the fact that they do not impair bradykinin clearance.
Option C: Option C is incorrect. ACE inhibitor cough is not mediated through angiotensin II effects on airway mucus secretion or mechanoreceptor stimulation from mucus accumulation. The mechanism is bradykinin-mediated C-fiber activation. Furthermore, ARBs block AT1 receptors, not ACE, so angiotensin II production is actually increased by the compensatory rise in renin when AT1 is blocked — angiotensin II is not absent with ARB therapy.
Option D: Option D is incorrect on two counts. While substance P is also a neprilysin substrate and can contribute to cough in some contexts, the primary mechanism of ACEi cough is bradykinin accumulation, not substance P. More critically, ARBs do not block AT2 receptors; they are selective for AT1. Substance P release from airway C-fibers is not mediated through AT2 receptor stimulation.
Option E: Option E is incorrect. The mechanism described — bronchoconstriction from reduced angiotensin I to II conversion — is not the established mechanism of ACEi cough. Angiotensin II does not produce bronchodilation via AT1 receptors in a clinically relevant way that would protect against cough. The reflex bronchoconstriction model does not account for the bradykinin-mediated C-fiber activation that is the confirmed pharmacological basis of ACEi cough.
3. A 67-year-old man with HFrEF (ejection fraction 28%), NYHA class II symptoms, blood pressure 126/78 mmHg, and eGFR 58 mL/min/1.73 m² has been stable on enalapril 10 mg twice daily, carvedilol 25 mg twice daily, and spironolactone 25 mg daily for nine months. He asks his cardiologist whether switching to sacubitril-valsartan is worth the increased cost and added complexity of the 36-hour washout transition. Which of the following statements best applies the PARADIGM-HF evidence to counsel this patient?
A) Sacubitril-valsartan is not indicated for patients already well-controlled on enalapril because PARADIGM-HF demonstrated benefit only in patients who had previously failed or were intolerant of ACE inhibitor therapy; stable patients on enalapril should remain on their current regimen
B) Sacubitril-valsartan should be offered only to patients with ejection fraction below 25% because the PARADIGM-HF mortality benefit was statistically significant only in the most severely impaired subgroup; at an ejection fraction of 28% the trial data do not support substitution
C) The magnitude of benefit from sacubitril-valsartan over enalapril in PARADIGM-HF was modest and driven entirely by reduction in heart failure hospitalizations, with no statistically significant effect on cardiovascular mortality; the decision to switch should be guided by hospitalization history rather than mortality risk
D) PARADIGM-HF demonstrated that sacubitril-valsartan reduced the composite of cardiovascular death or first heart failure hospitalization by 20% and all-cause mortality by 16% compared to enalapril over a median of 27 months; the NNT (number needed to treat) to prevent one primary endpoint event was approximately 21, comparing favorably to the NNTs for beta-blockers and mineralocorticoid receptor antagonists in HFrEF; this patient meets all eligibility criteria and the evidence supports offering the transition
E) Sacubitril-valsartan produced its benefit in PARADIGM-HF primarily through the valsartan component's superior AT1 blockade compared to enalapril's ACE inhibition; patients already on an ARB rather than an ACEi would not benefit from switching to sacubitril-valsartan because the AT1 blockade component is already provided
ANSWER: D
Rationale:
Option D is correct. PARADIGM-HF enrolled patients who were tolerating ACEi or ARB therapy — precisely the profile of this patient — and demonstrated that sacubitril-valsartan reduced the primary composite of cardiovascular death or first heart failure hospitalization by 20% relative to enalapril (hazard ratio 0.80; 95% CI 0.73–0.87; p less than 0.001), reduced all-cause mortality by 16%, and reduced cardiovascular mortality by 20%. The NNT (number needed to treat) of approximately 21 to prevent one primary endpoint event over 27 months compares favorably with the NNTs for beta-blockers (NNT approximately 28 for mortality in MERIT-HF) and mineralocorticoid receptor antagonists (NNT approximately 9 for the composite in RALES, but absolute risk reduction varies substantially by baseline risk). Benefit was consistent across all prespecified subgroups, including patients previously on ACEi and those on ARBs, and across the range of ejection fractions studied (up to 40%, later amended to 35%). This patient has an ejection fraction of 28%, NYHA class II symptoms, adequate blood pressure, and eGFR above 30 mL/min/1.73 m² — he meets all PARADIGM-HF eligibility criteria and 2022 AHA/ACC/HFSA guideline Class I, LOE A criteria for substitution. The 36-hour washout is a manageable transition step, not a contraindication.
Option A: Option A is incorrect. PARADIGM-HF enrolled patients tolerating ACEi or ARB therapy, not only those who had failed or were intolerant of ACEi. The trial population was predominantly composed of stable patients on background neurohormonal therapy — the same clinical profile as this patient. Current guidelines recommend offering sacubitril-valsartan substitution to symptomatic HFrEF patients on ACEi or ARB who can tolerate RAAS blockade, regardless of prior ACEi failure.
Option B: Option B is incorrect. PARADIGM-HF enrolled patients with ejection fraction at or below 40% (later protocol-amended to at or below 35%) and demonstrated consistent benefit across the range of ejection fractions studied; there was no prespecified subgroup analysis restricting benefit to ejection fractions below 25%. An ejection fraction of 28% is well within the range studied and supported.
Option C: Option C is incorrect. PARADIGM-HF demonstrated statistically significant reductions in both cardiovascular mortality (20% relative reduction) and all-cause mortality (16% relative reduction), in addition to heart failure hospitalization. The characterization of the benefit as driven entirely by hospitalization reduction with no cardiovascular mortality effect is factually incorrect and would lead to inappropriate withholding of a mortality-reducing therapy.
Option E: Option E is incorrect. The benefit of sacubitril-valsartan over enalapril is not attributable solely to superior AT1 blockade from the valsartan component; it derives from the dual mechanism of neprilysin inhibition plus AT1 blockade acting synergistically. Patients on ARB monotherapy were specifically included in PARADIGM-HF, and the benefit of transitioning from ARB to sacubitril-valsartan is well established because the neprilysin inhibition component — amplifying natriuretic peptide counter-regulation — adds a mechanism entirely absent from ARB monotherapy.
4. A 70-year-old man with HFrEF and stage 3 CKD (chronic kidney disease; eGFR 42 mL/min/1.73 m²) was transitioned from enalapril to sacubitril-valsartan 49 mg/51 mg twice daily three weeks ago. Today's laboratory results show serum creatinine 1.62 mg/dL (baseline 1.27 mg/dL, a 28% increase), potassium 5.1 mEq/L (baseline 4.4 mEq/L), blood pressure 108/70 mmHg, and no peripheral edema. He reports mild lightheadedness when standing. Which of the following most accurately applies the monitoring thresholds for sacubitril-valsartan to guide the next clinical step?
A) Both the creatinine rise and the potassium level exceed acceptable thresholds; sacubitril-valsartan should be discontinued immediately and the patient should be transitioned back to enalapril after a 36-hour washout period
B) The creatinine rise of 28% is within the acceptable threshold of 30% and does not mandate dose reduction; the potassium of 5.1 mEq/L is below the 5.5 mEq/L threshold for dose adjustment; the lightheadedness likely reflects the vasodilatory effect of neprilysin inhibition and AT1 blockade on a patient who may be relatively volume-depleted; the appropriate next step is to assess volume status and consider adjusting diuretic dose, not to reduce or stop sacubitril-valsartan
C) The creatinine rise of 28% exceeds the acceptable threshold of 20% for RAAS-blocking agents; sacubitril-valsartan dose should be reduced from 49/51 mg to 24/26 mg twice daily and the patient should be rechecked in one week with nephrology referral
D) The potassium of 5.1 mEq/L requires immediate dose reduction of sacubitril-valsartan because any potassium above 5.0 mEq/L in a CKD patient on RAAS blockade represents a contraindication to continuation at the current dose; the creatinine rise is within acceptable limits and does not require action
E) Both the creatinine and potassium findings are within acceptable ranges; no change in management is needed and the patient should return in three months for repeat laboratory testing as per standard follow-up intervals for stable HFrEF patients
ANSWER: B
Rationale:
Option B is correct. The established monitoring thresholds for RAAS-blocking agents, including sacubitril-valsartan, specify that a creatinine rise of up to 30% above baseline is acceptable and does not mandate dose reduction in the absence of oliguria, severe hyperkalemia, or clinical signs of acute kidney injury. This patient's 28% creatinine rise (from 1.27 to 1.62 mg/dL) is within that threshold. The potassium threshold for dose adjustment with sacubitril-valsartan is 5.5 mEq/L; a potassium of 5.1 mEq/L warrants monitoring and dietary counseling but does not require dose reduction or discontinuation. The lightheadedness is consistent with the combined vasodilatory effect of neprilysin inhibition (elevated ANP and BNP) and AT1 blockade, which may be accentuated if the patient is volume-depleted from diuretic therapy. Reviewing the furosemide dose and assessing volume status is the clinically appropriate intervention; reducing or stopping a guideline-recommended, mortality-reducing therapy based on laboratory values within acceptable ranges would not be appropriate.
Option A: Option A is incorrect. Neither the creatinine rise nor the potassium level exceeds the established thresholds for discontinuation. Discontinuing sacubitril-valsartan based on these values would deny the patient a guideline-recommended therapy. If transitioning back to an ACEi were clinically necessary, the 36-hour washout applies in the sacubitril-valsartan to ACEi direction, but that transition is not indicated here.
Option C: Option C is incorrect. The accepted creatinine rise threshold for RAAS-blocking agents is 30%, not 20%. Applying a 20% threshold is overly restrictive and not supported by the prescribing information or clinical guidelines for sacubitril-valsartan or ACEi/ARB therapy. A 28% creatinine rise does not meet the threshold for dose reduction under current standards.
Option D: Option D is incorrect. Potassium of 5.1 mEq/L does not constitute a contraindication to continuation of sacubitril-valsartan at the current dose. The threshold for dose adjustment based on hyperkalemia is 5.5 mEq/L; values between 5.0 and 5.5 mEq/L warrant monitoring, dietary sodium and potassium counseling, and reassessment, but not dose reduction. Applying a 5.0 mEq/L cutoff would generate unnecessary dose reductions in many patients with CKD and would not be consistent with the prescribing information.
Option E: Option E is incorrect. While the laboratory values are within acceptable thresholds and do not require dose adjustment, the patient's lightheadedness is a clinical symptom that requires evaluation and management. Returning in three months without addressing the volume status and diuretic dosing question ignores a clinically actionable finding and would leave the patient symptomatic without intervention.
5. A 73-year-old woman with HFrEF has been on sacubitril-valsartan 97 mg/103 mg twice daily for five months. She presents with two-week history of increased exertional dyspnea and one episode of orthopnea. Her BNP is 610 pg/mL. An urgent echocardiogram shows ejection fraction unchanged at 30%, with no new wall motion abnormality and estimated filling pressures mildly elevated. The emergency physician interprets the BNP as evidence of significant decompensation and plans IV diuresis. The cardiology fellow disagrees and orders a different test. Which of the following best explains the fellow's reasoning and identifies the correct next biomarker?
A) The fellow suspects right ventricular dysfunction as the cause of elevated BNP and orders a right heart catheterization rather than a different natriuretic peptide assay, because BNP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) are produced in equal proportions by both the right and left ventricles and neither is interpretable in isolation
B) The fellow recognizes that BNP levels above 400 pg/mL are diagnostic of acute decompensated heart failure regardless of medication status, and orders a troponin to evaluate for concurrent myocardial injury as the precipitant; the BNP alone confirms the decompensation and IV diuresis is appropriate
C) The fellow suspects the elevated BNP reflects underlying renal insufficiency rather than cardiac decompensation, because BNP is primarily renally cleared; ordering a creatinine clearance measurement will determine whether the BNP elevation is renal or cardiac in origin
D) The fellow orders repeat BNP in 24 hours to establish a trend, reasoning that a single elevated BNP value is not interpretable in sacubitril-treated patients but that a rising trend over 24 hours confirms decompensation even in the setting of neprilysin inhibition
E) The fellow orders NT-proBNP because BNP is a direct neprilysin substrate; sacubitril-mediated neprilysin inhibition impairs BNP degradation and causes BNP levels to rise artifactually independent of true hemodynamic status; NT-proBNP is not a neprilysin substrate and reflects actual ventricular wall stress, making it the valid monitoring biomarker in this patient
ANSWER: E
Rationale:
Option E is correct. BNP is degraded by neprilysin through direct enzymatic cleavage; sacubitril inhibits neprilysin, impairing BNP clearance and causing BNP to accumulate independent of the degree of cardiac decompensation. A BNP of 610 pg/mL in a patient on sacubitril-valsartan cannot be interpreted as it would be in a RAAS-naive patient, because an unknown proportion of the elevation reflects impaired enzymatic clearance rather than increased ventricular wall stress. NT-proBNP (the N-terminal prohormone fragment co-secreted with BNP) is not a neprilysin substrate; it is cleared by renal excretion and receptor-mediated pathways that are unaffected by sacubitril. NT-proBNP levels therefore accurately reflect ventricular wall stress in sacubitril-treated patients and are the recommended monitoring biomarker. The echocardiographic finding of unchanged ejection fraction and only mildly elevated filling pressures suggests the clinical picture may be less decompensated than the BNP implies; NT-proBNP will help resolve this ambiguity and guide the decision about IV diuresis appropriately.
Option A: Option A is incorrect. NT-proBNP and BNP differ critically in their relationship to neprilysin: BNP is a substrate and rises artifactually with sacubitril; NT-proBNP is not and remains valid. This distinction — not right ventricular versus left ventricular origin — is the pharmacological basis for the fellow's disagreement. Right heart catheterization is not the appropriate next step based on the information provided.
Option B: Option B is incorrect. BNP thresholds for heart failure diagnosis are established in the general population, not in patients on sacubitril-valsartan. The prescribing information and heart failure guidelines explicitly state that BNP is not a valid monitoring biomarker in sacubitril-treated patients because neprilysin inhibition raises BNP artifactually. Applying a standard BNP cutoff to a patient on sacubitril-valsartan would be an interpretive error that could lead to unnecessary IV diuresis.
Option C: Option C is incorrect. BNP is partially cleared renally, and renal insufficiency does elevate BNP; however, this is not the pharmacological basis of the fellow's concern. The primary issue is that sacubitril-mediated neprilysin inhibition raises BNP through an enzymatic clearance mechanism entirely separate from renal clearance. NT-proBNP, not creatinine clearance, is the appropriate next test.
Option D: Option D is incorrect. A rising BNP trend over 24 hours is not a validated method for interpreting BNP in sacubitril-treated patients. Because neprilysin inhibition chronically impairs BNP degradation, BNP levels remain persistently elevated above untreated baselines throughout the treatment course; serial BNP trends in this context do not reliably distinguish stable from decompensating hemodynamics. NT-proBNP is the appropriate biomarker for this purpose.
6. A 60-year-old man is hospitalized five days after a large anterior ST-elevation myocardial infarction (STEMI) treated with primary PCI (percutaneous coronary intervention). Echocardiography shows ejection fraction of 33% with anterior wall hypokinesis. He is started on carvedilol and aspirin, but develops worsening cough on day 3 of captopril, which is discontinued. His cardiologist needs to select an evidence-based neurohormonal agent to substitute for the ACEi in this post-MI left ventricular dysfunction context. Which of the following best applies the available outcomes evidence to guide drug selection?
A) Candesartan is the preferred ARB in post-MI left ventricular dysfunction based on CHARM-Alternative, which demonstrated mortality reduction in ACEi-intolerant patients with left ventricular dysfunction following myocardial infarction, and should be initiated at 4 mg daily with titration to 32 mg daily
B) No ARB has demonstrated outcomes benefit specifically in post-MI patients with left ventricular dysfunction; ARBs are approved only for hypertension and chronic HFrEF in the outpatient setting, and this patient should be managed with beta-blocker monotherapy until ejection fraction recovery is assessed at 90 days
C) Valsartan is the appropriate ARB in this setting, supported by the VALIANT trial, which established valsartan as non-inferior to captopril for reducing all-cause mortality in patients with MI complicated by left ventricular systolic dysfunction or heart failure; it should be initiated at low dose and titrated as tolerated, with the same 30% creatinine rise threshold applied during uptitration
D) Losartan is the preferred agent in post-MI left ventricular dysfunction because it is the only ARB with demonstrated superiority over ACEi for reducing sudden cardiac death in this population; the ELITE II trial established this indication at a target dose of 100 mg daily
E) Irbesartan is the evidence-based choice for post-MI left ventricular dysfunction based on IDNT trial data showing renoprotection and cardiovascular mortality reduction in high-risk diabetic patients, a population that overlaps substantially with post-MI patients with left ventricular dysfunction
ANSWER: C
Rationale:
Option C is correct. The VALIANT (Valsartan in Acute Myocardial Infarction) trial enrolled 14,703 patients with MI complicated by left ventricular systolic dysfunction, clinical heart failure, or both, and compared valsartan, captopril, and the combination. The valsartan-alone arm demonstrated non-inferiority to captopril for all-cause mortality — the primary endpoint — with a hazard ratio of 1.00 (97.5% CI 0.90–1.11), establishing valsartan as a statistically equivalent alternative to ACEi in this specific post-MI population. This is the only large outcomes trial demonstrating ARB efficacy in the early post-MI setting with left ventricular dysfunction, making valsartan the evidence-based agent of choice when ACEi cannot be tolerated. Initiation should follow the same approach as post-MI ACEi therapy — low starting dose with gradual uptitration — and the same monitoring thresholds (creatinine rise up to 30%, potassium below 5.5 mEq/L) apply. The VALIANT combination arm showed no mortality benefit over either monotherapy and more adverse effects, reinforcing that valsartan should replace, not supplement, ACEi in this context.
Option A: Option A is incorrect. CHARM-Alternative enrolled patients with chronic HFrEF intolerant of ACEi and compared candesartan to placebo; it was not a post-MI trial. The pivotal evidence for ARB use in post-MI left ventricular dysfunction is VALIANT (valsartan), not CHARM-Alternative (candesartan). Applying candesartan based on CHARM-Alternative data to the early post-MI setting conflates two different patient populations and two different clinical contexts.
Option B: Option B is incorrect. VALIANT directly established ARB efficacy in post-MI left ventricular dysfunction, making the claim that no ARB has demonstrated outcomes benefit in this setting factually incorrect. Beta-blocker monotherapy without neurohormonal blockade of the RAAS would leave the patient without a guideline-recommended component of post-MI therapy and would not be consistent with current ACC/AHA STEMI management guidelines.
Option D: Option D is incorrect. Losartan has not demonstrated superiority over ACEi for sudden cardiac death reduction in post-MI patients. ELITE II compared losartan to captopril in elderly heart failure patients and found no significant difference in all-cause mortality; losartan did not show superiority. The specific post-MI indication with demonstrated non-inferiority data belongs to valsartan via VALIANT, not losartan.
Option E: Option E is incorrect. IDNT evaluated irbesartan in patients with type 2 diabetic nephropathy and overt proteinuria; it was a renal outcomes trial in CKD, not a cardiovascular mortality trial in post-MI patients with left ventricular dysfunction. Extrapolating IDNT renoprotection data to the post-MI left ventricular dysfunction indication is not appropriate, and irbesartan does not carry this indication.
7. A 65-year-old woman with HFrEF (ejection fraction 32%) and a history of lisinopril-induced cough has been managed on valsartan 160 mg twice daily, carvedilol 25 mg twice daily, and eplerenone 25 mg daily for 14 months. Her cardiologist decides to upgrade to sacubitril-valsartan. The resident asks whether a washout period is required before initiating sacubitril-valsartan in a patient transitioning from valsartan monotherapy rather than from an ACEi. Which of the following correctly applies the washout rule to this transition?
A) No washout period is required when transitioning from ARB monotherapy to sacubitril-valsartan; the 36-hour washout applies specifically to ACEi-to-ARNI and ARNI-to-ACEi transitions and is pharmacodynamically grounded in the risk of simultaneous ACE and neprilysin inhibition raising bradykinin to angioedema-producing levels; ARBs do not inhibit ACE or neprilysin and therefore do not contribute to bradykinin accumulation when sacubitril is added
B) A 24-hour washout from valsartan is required before initiating sacubitril-valsartan to prevent additive AT1 receptor blockade from the valsartan component of the new combination overlapping with residual valsartan from the prior monotherapy regimen, which could produce excessive hypotension during the transition period
C) A 36-hour washout from valsartan is required because valsartan inhibits CYP2C9 and this enzyme is responsible for the esterase-mediated activation of sacubitril to LBQ657; residual valsartan would impair sacubitril activation and reduce the neprilysin inhibition component of the combination during the critical initiation period
D) A washout of at least 7 days from any ARB is required before initiating sacubitril-valsartan because high-affinity AT1 receptor binding by ARBs persists for days after the last dose; initiating sacubitril-valsartan before full AT1 receptor dissociation risks supra-therapeutic receptor blockade and severe hypotension
E) The washout requirement for ARB-to-ARNI transition is determined by the ARB's half-life; valsartan has a half-life of approximately 6 hours, so a minimum of 5 half-lives (30 hours) must elapse before initiating sacubitril-valsartan to ensure complete valsartan clearance and prevent pharmacodynamic overlap
ANSWER: A
Rationale:
Option A is correct. The mandatory 36-hour washout applies exclusively to transitions involving an ACE inhibitor — specifically ACEi to sacubitril-valsartan and sacubitril-valsartan back to ACEi. The pharmacodynamic rationale is precise: ACE inhibitors and sacubitril both raise bradykinin by blocking two of its three principal enzymatic inactivation pathways (ACE and neprilysin respectively); simultaneous inhibition of both pathways produces bradykinin accumulation substantially greater than either agent alone, creating clinically significant angioedema risk. ARBs do not inhibit ACE or neprilysin and therefore do not contribute to bradykinin accumulation regardless of when sacubitril is initiated. When transitioning from ARB monotherapy to sacubitril-valsartan, the valsartan component of the new combination replaces the prior ARB at the AT1 receptor without any pharmacodynamic interaction that would justify a washout period. The prescribing information for sacubitril-valsartan explicitly states that no washout is required when transitioning from an ARB.
Option B: Option B is incorrect. Additive AT1 receptor blockade from brief overlap of valsartan monotherapy with the valsartan component of sacubitril-valsartan is not a pharmacodynamically distinct risk requiring a 24-hour washout. The clinical concern with any RAAS-blocking initiation is hypotension, which is managed by starting at the lowest dose and monitoring blood pressure — not by instituting an arbitrary washout period from a non-ACEi RAAS agent. The prescribing information does not require a washout for ARB-to-ARNI transition.
Option C: Option C is incorrect on two counts. Valsartan does not inhibit CYP2C9; it is not a relevant inhibitor of this enzyme in clinical use. Additionally, sacubitril is not activated by CYP2C9; its conversion to the active metabolite LBQ657 is mediated by plasma and tissue esterases, not by CYP2C9-dependent oxidative metabolism. The proposed interaction mechanism is pharmacologically implausible.
Option D: Option D is incorrect. ARB dissociation from the AT1 receptor is not so prolonged as to require a 7-day washout; ARB pharmacodynamic effects resolve with a time course consistent with the drug's plasma half-life, not with an extended receptor-bound phase. No clinical data or prescribing guidance supports a 7-day ARB washout before ARNI initiation.
Option E: Option E is incorrect. The washout requirement for ACEi-to-ARNI transition is pharmacodynamically grounded in the angioedema risk from combined ACE and neprilysin inhibition, not in the half-life arithmetic of ACEi clearance alone; and crucially, this pharmacodynamic rationale does not apply to ARBs at all. Applying a half-life–based washout calculation to valsartan before sacubitril-valsartan initiation invents a requirement that does not exist in the prescribing information or clinical guidelines.
8. A 58-year-old African American man with HFrEF (ejection fraction 30%), NYHA class II symptoms, blood pressure 118/74 mmHg, and eGFR 55 mL/min/1.73 m² has been stable on valsartan 160 mg twice daily, carvedilol 25 mg twice daily, and spironolactone 25 mg daily. He has no prior history of angioedema. His cardiologist proposes transitioning to sacubitril-valsartan. The pharmacist asks whether any race-specific risk modification is required. Which of the following most accurately characterizes the angioedema risk and the appropriate clinical approach in this patient?
A) African American patients are contraindicated from sacubitril-valsartan based on PARADIGM-HF subgroup data showing angioedema rates exceeding 5% in this population; current guidelines recommend against ARNI use in African American patients and specify ARB monotherapy as the preferred neurohormonal strategy
B) No race-specific risk modification is required; angioedema with sacubitril-valsartan is equally distributed across racial groups in PARADIGM-HF, and the overall rate of 0.45% applies uniformly; this patient should be counseled using the same risk language as any other HFrEF patient
C) African American patients should receive a test dose of sacubitril-valsartan 24 mg/26 mg under observation in the clinic for two hours before being prescribed the drug for home use, because the higher angioedema susceptibility in this population requires direct observation during first exposure
D) African American patients have approximately a 2.4-fold higher angioedema rate with sacubitril-valsartan compared to non-African American patients in PARADIGM-HF (approximately 2.4% versus 0.5%); the drug is not contraindicated in this patient who has no prior angioedema history, but he should receive explicit counseling about angioedema symptoms — particularly tongue, lip, and laryngeal swelling — and instructed to seek emergency care immediately if these occur; the absence of prior ACEi angioedema means ARNI is not contraindicated
E) African American patients require a longer 48-hour washout from valsartan before starting sacubitril-valsartan, rather than the standard no-washout protocol, because the higher bradykinin responsiveness in this population means residual ARB receptor occupancy from valsartan increases the angioedema risk during the initiation period
ANSWER: D
Rationale:
Option D is correct. PARADIGM-HF subgroup data showed that angioedema occurred in approximately 2.4% of African American patients randomized to sacubitril-valsartan compared with approximately 0.5% of enalapril-treated African American patients — a substantially higher rate than the overall trial population (0.45% sacubitril-valsartan versus 0.24% enalapril). This racial disparity in bradykinin-mediated angioedema susceptibility is well established and reflects known pharmacogenomic and physiological differences in bradykinin metabolism and vascular responsiveness in this population, not a specific drug intolerance. Importantly, higher susceptibility does not constitute a contraindication in a patient with no prior history of angioedema on ACEi or ARNI. The appropriate clinical approach is to proceed with sacubitril-valsartan — which carries a Class I, LOE A guideline recommendation regardless of race — while providing explicit, detailed counseling about angioedema recognition (tongue, lip, laryngeal swelling, stridor) and the need for immediate emergency evaluation if symptoms occur. This patient, transitioning from valsartan with no prior angioedema history, is eligible for ARNI therapy with heightened monitoring.
Option A: Option A is incorrect. Sacubitril-valsartan is not contraindicated in African American patients; the 2022 AHA/ACC/HFSA guidelines recommend it with Class I, LOE A for eligible HFrEF patients regardless of race. The PARADIGM-HF angioedema rate of approximately 2.4% in African American patients, while elevated, does not exceed a threshold that triggers contraindication in patients without prior angioedema history. The drug's mortality benefit applies to this population and should not be withheld based on race alone.
Option B: Option B is incorrect. PARADIGM-HF data did demonstrate a race-specific difference in angioedema rates; the 0.45% overall rate is not applicable uniformly across racial groups. African American patients have a substantially higher rate (approximately 2.4%), which is clinically meaningful and requires specific counseling. Failing to communicate this elevated risk would be inadequate informed consent.
Option C: Option C is incorrect. There is no standard clinical protocol requiring in-office observation of the first sacubitril-valsartan dose for African American patients or any other patient population without a specific prior reaction history. Angioedema with neprilysin inhibitors typically develops over hours to days, not within the two-hour window described. The appropriate risk management is thorough counseling, not supervised first dosing.
Option E: Option E is incorrect. The washout requirement for ARB-to-ARNI transition is none — regardless of race. ARBs do not inhibit ACE or neprilysin and therefore do not contribute to bradykinin accumulation when sacubitril is added. Applying a race-modified washout period from valsartan has no pharmacological basis; higher bradykinin responsiveness in African American patients is a receptor-level sensitivity, not a pharmacokinetic interaction altered by ARB residual receptor occupancy.
9. A cardiology fellow asks why neprilysin inhibition with sacubitril produces cardiovascular benefits — including reduced cardiac fibrosis, suppressed renin and aldosterone, and systemic vasodilation — that are not replicated by increasing furosemide doses to achieve equivalent natriuresis in a patient with decompensated HFrEF. Which of the following most accurately explains the mechanistic distinction?
A) Furosemide and natriuretic peptides produce identical natriuresis through the same collecting duct sodium channel inhibition pathway; the cardiovascular benefits of neprilysin inhibition are therefore also replicated by furosemide at equivalent natriuretic doses, and the fellow's premise is incorrect
B) Furosemide blocks the NKCC2 (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle to produce natriuresis; it does not activate NPR-A (natriuretic peptide receptor A) or generate cGMP (cyclic guanosine monophosphate) signaling; the cardiovascular effects of elevated ANP and BNP — vasodilation through vascular smooth muscle cGMP, aldosterone suppression at the adrenal cortex, renin suppression at juxtaglomerular cells, and anti-fibrotic signaling in cardiac fibroblasts — are receptor-mediated actions requiring NPR-A activation that furosemide does not provide
C) Furosemide is inferior to natriuretic peptides solely because it causes hypokalemia and volume depletion; correcting these electrolyte abnormalities with potassium supplementation and volume replacement would allow furosemide to replicate the full cardiovascular benefit of neprilysin inhibition at equivalent natriuretic doses
D) The advantage of neprilysin inhibition over furosemide is entirely attributable to the valsartan component of sacubitril-valsartan; natriuretic peptide receptor activation by elevated ANP and BNP provides no cardiovascular benefit independent of AT1 blockade, and furosemide combined with an ARB would replicate the full benefit of sacubitril-valsartan
E) Furosemide produces reflex sympathetic activation and RAAS upregulation through volume depletion, which is the only mechanistic difference from natriuretic peptide-mediated diuresis; this reflex activation can be blocked by combining furosemide with a beta-blocker, which would restore equivalence with the cardiovascular benefits of neprilysin inhibition
ANSWER: B
Rationale:
Option B is correct. The natriuretic and cardiovascular actions of ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide) are mediated through NPR-A (natriuretic peptide receptor A), a transmembrane receptor with intrinsic guanylyl cyclase activity that generates cGMP as the intracellular second messenger. cGMP activates protein kinase G in multiple tissues: in vascular smooth muscle, producing vasodilation; in adrenal zona glomerulosa cells, suppressing aldosterone secretion independently of angiotensin II; in juxtaglomerular cells, suppressing renin secretion; and in cardiac fibroblasts, inhibiting proliferation and collagen deposition — an anti-fibrotic effect relevant to preventing adverse cardiac remodeling. Furosemide blocks NKCC2 in the thick ascending limb of Henle's loop to produce natriuresis by a mechanism entirely independent of NPR-A and cGMP. Increasing furosemide does not activate NPR-A, does not generate cGMP in vascular smooth muscle or adrenal tissue, does not suppress aldosterone or renin through the natriuretic peptide receptor axis, and does not produce anti-fibrotic cGMP signaling in cardiac fibroblasts. The cardiovascular benefits of elevated natriuretic peptides via sacubitril are therefore receptor-specific and cannot be replicated by dose-escalating a loop diuretic that does not use this signaling pathway.
Option A: Option A is incorrect. Furosemide and natriuretic peptides do not produce natriuresis through the same collecting duct sodium channel pathway. Furosemide acts in the thick ascending limb at NKCC2; natriuretic peptides act in the collecting duct via cGMP-mediated effects on sodium channels. They are mechanistically distinct at the renal tubular level, and the broader cardiovascular signaling of natriuretic peptides through NPR-A/cGMP has no equivalent in furosemide's mechanism.
Option C: Option C is incorrect. The mechanistic distinction between furosemide and natriuretic peptides is not primarily related to electrolyte disturbances from furosemide; it is a fundamental receptor-signaling difference. Correcting furosemide-induced hypokalemia does not confer NPR-A activation or cGMP-mediated cardiovascular effects. Volume replacement would also negate the natriuretic purpose of the furosemide.
Option D: Option D is incorrect. The cardiovascular benefits of sacubitril-valsartan derive from both the neprilysin inhibition component (elevated natriuretic peptides providing vasodilation, aldosterone and renin suppression, and anti-fibrotic signaling through NPR-A/cGMP) and the AT1 blockade component (suppression of angiotensin II-mediated vasoconstriction, aldosterone, and remodeling). These two mechanisms are synergistic; the natriuretic peptide signaling provides benefit independent of and additive to AT1 blockade.
Option E: Option E is incorrect. Furosemide's disadvantageous neurohormonal consequences — reflex sympathetic activation and RAAS upregulation through volume depletion — are real and clinically relevant, but they are not the only mechanistic difference. Even if reflex RAAS activation were completely abolished by beta-blockade, furosemide would still not activate NPR-A, generate vascular cGMP, suppress aldosterone through the natriuretic peptide axis, or produce anti-fibrotic cGMP signaling. The absence of NPR-A activation is inherent to furosemide's mechanism regardless of neurohormonal co-treatment.
10. A 52-year-old man with type 2 diabetes for 14 years presents with urine albumin-to-creatinine ratio of 820 mg/g, serum creatinine 1.5 mg/dL (eGFR 48 mL/min/1.73 m²), and blood pressure 142/88 mmHg on amlodipine 10 mg daily. He has no history of heart failure or coronary disease. His nephrologist recommends adding an ARB for renoprotection. A medical student asks whether the ARB benefit is simply a blood pressure effect or whether it provides additional renal protection beyond what amlodipine has already achieved. Which of the following most accurately addresses this question using the available outcomes evidence?
A) The renoprotective benefit of ARBs in diabetic nephropathy is entirely attributable to blood pressure reduction; head-to-head trials comparing ARBs to calcium channel blockers at matched blood pressures have shown equivalent rates of ESRD progression, confirming that any antihypertensive agent achieving the same blood pressure target provides equal renal protection
B) ARBs provide additional renoprotection beyond blood pressure lowering only in patients with type 1 diabetes; in type 2 diabetic nephropathy, the benefit of ARBs is equivalent to that of calcium channel blockers at the same blood pressure, and the choice between agents should be based on tolerability and cost
C) The renoprotective benefit of ARBs in diabetic nephropathy is mediated entirely through aldosterone suppression; because amlodipine does not suppress aldosterone, adding an ARB reduces aldosterone-driven mesangial matrix expansion and podocyte injury regardless of blood pressure effects
D) ARBs provide renoprotection in diabetic nephropathy through a dual mechanism: blood pressure reduction and direct inhibition of TGF-beta (transforming growth factor-beta) synthesis in mesangial cells through AT1 receptor blockade; amlodipine does not inhibit TGF-beta and therefore cannot provide the same degree of anti-fibrotic renal protection even at equivalent blood pressures
E) The IDNT trial (irbesartan) and RENAAL trial (losartan) established that ARBs reduce the composite of doubling of serum creatinine, ESRD, and all-cause mortality in type 2 diabetic nephropathy independently of blood pressure lowering; both trials were specifically designed with blood pressure matching to isolate the RAAS-mediated renoprotective effect, which operates through efferent arteriolar dilation reducing intraglomerular hypertension and proteinuria — a mechanism amlodipine does not provide
ANSWER: E
Rationale:
Option E is correct. The IDNT (Irbesartan Diabetic Nephropathy Trial) and RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trials were specifically designed to test whether ARBs provide renoprotection beyond blood pressure lowering in type 2 diabetic nephropathy with overt proteinuria. Both trials included an active comparator arm or used additional antihypertensive agents to match blood pressure between treatment groups, isolating the effect of AT1 blockade from blood pressure reduction. IDNT demonstrated that irbesartan significantly reduced the composite of doubling of serum creatinine, ESRD, or all-cause mortality compared to both placebo and amlodipine at matched blood pressure. RENAAL demonstrated similar results with losartan versus placebo with blood pressure matching. The mechanistic basis is AT1 receptor blockade preferentially dilating the efferent arteriole, reducing intraglomerular hydrostatic pressure and the filtered protein load that drives tubulointerstitial injury. Amlodipine, which dilates the afferent arteriole without preferential efferent effect, does not reduce intraglomerular pressure and provides no equivalent blood pressure–independent renoprotection in this population. This patient's albumin-to-creatinine ratio of 820 mg/g places him squarely in the overt nephropathy range where the trial evidence applies.
Option A: Option A is incorrect. IDNT specifically included an amlodipine arm at matched blood pressure and demonstrated that irbesartan outperformed amlodipine for the composite renal endpoint despite equivalent blood pressure control — directly refuting the claim that ARB renoprotection is purely a blood pressure effect. The renal advantage of ARBs over dihydropyridine calcium channel blockers in diabetic nephropathy is one of the best-established blood pressure–independent drug class effects in nephrology.
Option B: Option B is incorrect. IDNT and RENAAL enrolled exclusively type 2 diabetic patients with overt nephropathy — not type 1 diabetic patients — and demonstrated significant renoprotective benefit in this population. The pivotal ACEi renoprotection data in type 1 diabetic nephropathy came from the Captopril Trial (Lewis et al.); the ARB renal outcome data are specifically in type 2 diabetes. This option reverses the evidence base entirely.
Option C: Option C is incorrect. While aldosterone does contribute to renal fibrosis through mineralocorticoid receptor-mediated mesangial matrix expansion, this is not the established primary mechanism of ARB renoprotection in diabetic nephropathy. The primary IDNT and RENAAL mechanism operates through hemodynamic reduction of intraglomerular pressure via efferent arteriolar dilation and the resulting reduction in glomerular filtration of protein. Aldosterone suppression by ARBs is a secondary effect and does not account for the blood pressure–independent renoprotection documented in these trials.
Option D: Option D is incorrect. While AT1 receptor blockade does reduce TGF-beta expression in some experimental models, TGF-beta suppression is not the established primary mechanism cited in IDNT and RENAAL for blood pressure–independent renoprotection. The hemodynamic mechanism — efferent arteriolar dilation reducing intraglomerular hypertension — is the accepted mechanistic explanation for the trial outcomes. Presenting TGF-beta inhibition as the primary distinguishing mechanism overstates a secondary pathway and misrepresents the evidence.
11. A 79-year-old woman with HFrEF (ejection fraction 25%), NYHA class III symptoms, and no prior RAAS-blocking therapy is seen in heart failure clinic. Her resting blood pressure is 96/62 mmHg. She is on furosemide 80 mg daily, carvedilol 6.25 mg twice daily, and spironolactone 25 mg daily. Her cardiologist wishes to initiate sacubitril-valsartan. Which of the following most accurately applies the prescribing guidance for sacubitril-valsartan initiation in this patient?
A) Sacubitril-valsartan is absolutely contraindicated when systolic blood pressure is below 100 mmHg; this patient should not receive ARNI therapy until her systolic blood pressure has been optimized above 100 mmHg, which may require reduction of furosemide and temporary fluid loading
B) Sacubitril-valsartan should be initiated at the target dose of sacubitril 97 mg / valsartan 103 mg twice daily in all RAAS-naive patients regardless of blood pressure, because RAAS-naive patients have greater RAAS activation and therefore greater AT1 receptor–mediated vasoconstriction that will maintain blood pressure during initiation
C) Sacubitril-valsartan should be initiated at the intermediate dose of sacubitril 49 mg / valsartan 51 mg twice daily in this patient; the lowest available dose is reserved only for patients with eGFR below 30 mL/min/1.73 m², and blood pressure below 100 mmHg is managed by reducing furosemide before initiating ARNI at the standard starting dose
D) Sacubitril-valsartan should be initiated at the lowest available dose of sacubitril 24 mg / valsartan 26 mg twice daily in this patient; low systolic blood pressure, volume depletion from diuretic therapy, and absence of prior RAAS-blocking therapy are all indications for lowest-dose initiation; hypotension from dual vasodilatory mechanisms — neprilysin inhibition elevating natriuretic peptides and AT1 blockade — is the most common adverse effect and is substantially amplified in this clinical profile
E) Sacubitril-valsartan initiation should be deferred until carvedilol is uptitrated to target dose of 25 mg twice daily, because beta-blockade at target dose provides a baroreflex-stabilizing effect that prevents the hypotension from sacubitril-valsartan initiation; initiating ARNI before beta-blocker target dose increases the risk of orthostatic syncope by 3-fold
ANSWER: D
Rationale:
Option D is correct. Hypotension is the most common adverse effect of sacubitril-valsartan in clinical practice, occurring in approximately 18% of patients in PARADIGM-HF. The mechanism involves two simultaneous vasodilatory pathways: neprilysin inhibition elevates ANP and BNP, which signal through NPR-A and cGMP to produce systemic vasodilation and natriuresis; AT1 blockade from valsartan simultaneously removes angiotensin II-mediated vasoconstriction and aldosterone-driven sodium retention. This combined vasodilatory effect is substantially amplified in patients with systolic blood pressure below 100 mmHg, patients on high-dose diuretics with possible relative volume depletion, and patients who have not previously been exposed to RAAS-blocking agents and therefore have higher baseline RAAS activation that will be acutely suppressed. Current prescribing guidance and heart failure guidelines recommend initiating sacubitril-valsartan at the lowest available dose — sacubitril 24 mg / valsartan 26 mg twice daily — in these high-risk patient profiles, with gradual titration over 2 to 4 weeks as tolerated. This patient meets all three lowest-dose initiation criteria simultaneously.
Option A: Option A is incorrect. Systolic blood pressure below 100 mmHg is not an absolute contraindication to sacubitril-valsartan; it is an indication for initiating at the lowest available dose with close monitoring. Withholding ARNI therapy and pursuing fluid loading to raise blood pressure before initiating a mortality-reducing guideline-recommended therapy is not consistent with current prescribing guidance and would delay benefit without pharmacological justification.
Option B: Option B is incorrect. Target-dose initiation regardless of blood pressure in a RAAS-naive patient with systolic blood pressure of 96 mmHg would carry substantial risk of symptomatic hypotension, renal hypoperfusion, and adverse outcomes. The rationale that RAAS-naive patients have greater angiotensin II-mediated vasoconstriction that will sustain blood pressure is pharmacologically inverted: acute AT1 blockade in a patient with high baseline RAAS activation produces a greater acute blood pressure reduction, not a protective effect.
Option C: Option C is incorrect. The lowest available dose of sacubitril-valsartan is indicated not only for eGFR below 30 mL/min/1.73 m² but also for patients with systolic blood pressure below 100 mmHg, significant volume depletion, and RAAS-naive status. The intermediate dose of sacubitril 49 mg / valsartan 51 mg is not the appropriate starting point for a patient with all three high-hypotension-risk features present simultaneously.
Option E: Option E is incorrect. There is no clinical guideline or prescribing requirement mandating beta-blocker uptitration to target dose before ARNI initiation. In clinical practice, sacubitril-valsartan is often initiated when patients are not yet at beta-blocker target dose; the two drug class titrations proceed in parallel under close monitoring. No 3-fold increase in orthostatic syncope risk from initiating ARNI before beta-blocker target dose is established in clinical trial data.
12. A 69-year-old man with type 2 diabetes, stage 3 CKD (eGFR 38 mL/min/1.73 m²), and hypertension has a urine albumin-to-creatinine ratio of 340 mg/g on ramipril 10 mg daily. His nephrologist reviews an older literature recommendation suggesting that adding telmisartan to ramipril provides additive proteinuria reduction and proposes the combination. The patient's cardiologist disagrees. Which of the following best applies the clinical evidence to resolve this disagreement?
A) The nephrologist is correct; ONTARGET demonstrated that the combination of telmisartan and ramipril produced greater reduction in proteinuria than either agent alone, and the renal benefit outweighs the modest increase in hypotension observed in the combination arm; the cardiologist's concern is overstated for a patient with CKD and proteinuria
B) Neither the cardiologist nor the nephrologist is correct; dual RAAS blockade is appropriate only when potassium is below 4.0 mEq/L at baseline, providing a safety margin for the expected hyperkalemia; this patient's potassium should be checked before deciding whether the combination is permissible
C) The cardiologist is correct; ONTARGET demonstrated that adding telmisartan to ramipril in high-risk patients (including those with diabetes and vascular disease) produced significantly more hypotension, acute kidney injury, hyperkalemia, and dialysis requirement than ramipril alone, without additional reduction in cardiovascular mortality or the primary composite endpoint; current guidelines explicitly contraindicate routine ACEi-ARB combination in this population
D) The cardiologist is correct but for the wrong reason; ACEi-ARB combination is contraindicated only in patients with eGFR below 30 mL/min/1.73 m²; this patient with eGFR of 38 mL/min/1.73 m² is above the threshold and could receive dual RAAS blockade under close monitoring with monthly creatinine and potassium checks
E) Both physicians are partially correct; ACEi-ARB combination is permissible for a defined trial period of 90 days to assess proteinuria response; if urine albumin-to-creatinine ratio declines by more than 30%, the combination should be continued; if it does not, the ARB should be discontinued
ANSWER: C
Rationale:
Option C is correct. ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) enrolled 25,620 high-risk patients — including those with diabetes, vascular disease, and CKD — and randomized them to telmisartan alone, ramipril alone, or the combination. This patient's clinical profile closely mirrors the ONTARGET population. The combination arm produced significantly more hypotension (4.8% versus 1.7% with ramipril alone), more syncope, more acute kidney injury, more requirement for dialysis, and more hyperkalemia than ramipril alone, without any reduction in the primary composite of cardiovascular death, MI, stroke, or heart failure hospitalization (16.3% versus 16.5%). Rather than showing renal benefit from combination therapy, ONTARGET demonstrated net renal harm. Based on this evidence, all major cardiology and nephrology guidelines — including ACC/AHA and KDIGO — explicitly contraindicate routine ACEi-ARB combination therapy. The older literature suggesting additive proteinuria reduction from small trials was superseded by the ONTARGET harm data in a much larger and more adequately powered population.
Option A: Option A is incorrect. ONTARGET did not show that the combination produced greater cardiovascular mortality reduction or net renal benefit that outweighed the adverse effects; the combination arm showed net harm in the renal endpoint (more dialysis) and no benefit in the cardiovascular composite endpoint. The nephrologist's position is not supported by the trial evidence that definitively settled this clinical question.
Option B: Option B is incorrect. Dual ACEi-ARB therapy is not conditionally permissible based on baseline potassium values; it is contraindicated as a matter of guideline-based prescribing regardless of the baseline potassium, based on the overall harm profile demonstrated in ONTARGET. Setting a potassium threshold as a safety criterion for combination therapy is not consistent with current evidence or prescribing recommendations.
Option D: Option D is incorrect. The contraindication to ACEi-ARB combination is not restricted to patients with eGFR below 30 mL/min/1.73 m²; ONTARGET demonstrated harm across the broad high-risk population it enrolled, which included patients with GFRs across a wide range. The harm signal for renal outcomes (more dialysis requirement) was observed in the trial population as a whole, not only in severely impaired patients. No eGFR threshold above which dual RAAS blockade is considered safe is established in current guidelines.
Option E: Option E is incorrect. There is no guideline-endorsed protocol for a 90-day ACEi-ARB combination trial period with proteinuria response as the decision criterion. ONTARGET's demonstration of net renal harm from combination therapy supersedes empirical trial-and-continue approaches based on proteinuria response. The combination is contraindicated as routine practice, not subject to an individualized response-based exemption.
13. A 71-year-old man with HFrEF was transitioned from enalapril to sacubitril-valsartan 97 mg/103 mg twice daily eight weeks ago. At his cardiology follow-up he reports feeling subjectively better — less dyspnea on exertion and improved exercise tolerance. His weight is unchanged, blood pressure is 110/68 mmHg, and there is no peripheral edema or elevated JVP (jugular venous pressure). However, his BNP has risen from 110 pg/mL (on enalapril, six months ago) to 420 pg/mL. The nurse practitioner covering the visit is concerned about decompensation and plans to increase his furosemide dose. The attending disagrees. Which of the following best explains the attending's reasoning and identifies the appropriate next step?
A) The BNP rise from 110 to 420 pg/mL is pharmacologically expected and does not indicate decompensation; sacubitril inhibits neprilysin, the primary enzyme responsible for BNP degradation, causing BNP to accumulate independent of ventricular wall stress; the appropriate next step is to order NT-proBNP, which is not a neprilysin substrate and therefore reflects true hemodynamic status; the patient's clinical picture — subjective improvement, stable weight, no edema, no elevated JVP — is more consistent with hemodynamic stability than decompensation
B) The BNP rise indicates that sacubitril-valsartan is not adequately suppressing neurohormonal activation in this patient; the appropriate response is to add a second neurohormonal agent such as ivabradine or hydralazine-isosorbide dinitrate to provide additional afterload reduction, because the rising BNP confirms ongoing adverse remodeling despite dual RAAS-neprilysin blockade
C) The BNP rise from 110 to 420 pg/mL confirms early decompensation; physical examination findings lag several days behind biomarker changes in HFrEF, and the BNP trend should be weighted more heavily than the clinical assessment; increasing furosemide by 20 mg daily is the correct immediate step, with repeat BNP in one week to confirm response
D) The attending recognizes that BNP levels above 400 pg/mL in any HFrEF patient on any medication regimen require urgent reassessment with echocardiography within 48 hours regardless of clinical symptoms, because the threshold value indicates a high probability of acute decompensation that physical examination may not detect until hemodynamic compromise is advanced
E) The BNP rise reflects an adverse drug interaction between sacubitril-valsartan and furosemide; furosemide upregulates ventricular BNP gene transcription through volume-depletion-mediated wall stress, and the combination of volume depletion with neprilysin inhibition amplifies BNP production rather than simply impairing its clearance; reducing furosemide by 50% is the appropriate next step
ANSWER: A
Rationale:
Option A is correct. BNP is a direct substrate for neprilysin; sacubitril inhibits neprilysin, impairing BNP degradation and causing plasma BNP to accumulate above the level that would be present based on ventricular wall stress alone. The rise from 110 to 420 pg/mL in this patient is therefore pharmacologically expected and cannot be interpreted using the standard BNP diagnostic thresholds established in non-sacubitril-treated populations. This is explicitly recognized in the sacubitril-valsartan prescribing information and heart failure guidelines, which specify that BNP is not a valid monitoring biomarker in ARNI-treated patients. NT-proBNP — which is co-secreted with BNP in equimolar amounts but is not a neprilysin substrate and is eliminated by renal and receptor-mediated clearance — remains a valid reflection of true ventricular wall stress in this context. The patient's clinical picture strongly argues against decompensation: subjective improvement in dyspnea and exercise tolerance, stable weight, absence of peripheral edema, and no elevated JVP. Increasing furosemide based on an artifactually elevated BNP in a clinically stable patient risks iatrogenic volume depletion and hypotension.
Option B: Option B is incorrect. The BNP rise does not indicate inadequate neurohormonal suppression or ongoing adverse remodeling; it reflects the pharmacological effect of neprilysin inhibition on BNP clearance. Adding a second neurohormonal agent in response to an artifactual BNP elevation without clinical evidence of decompensation would expose the patient to additional drug burden without justification. NT-proBNP should be measured to accurately assess neurohormonal status before any treatment escalation.
Option C: Option C is incorrect. Physical examination findings in HFrEF — weight gain, peripheral edema, elevated JVP, S3 gallop — are well-validated markers of decompensation that correlate with elevated filling pressures and are not simply delayed relative to biomarker changes. In this patient, the clinical examination is reassuring on all these parameters. The BNP elevation is artifactual in the context of sacubitril therapy, and escalating furosemide based on it would be inappropriate.
Option D: Option D is incorrect. The threshold-based interpretation of BNP applies in patients not receiving neprilysin inhibitors; it cannot be applied uniformly to sacubitril-treated patients. A BNP of 420 pg/mL in this patient reflects pharmacological drug effect, not a hemodynamic threshold requiring emergency echocardiography. The clinical assessment — the patient feeling better, with stable weight and no congestion signs — is the appropriate primary data source in this scenario, supplemented by NT-proBNP.
Option E: Option E is incorrect. Furosemide does not upregulate BNP gene transcription through a pharmacological drug interaction with sacubitril; the BNP rise is not a production effect but a clearance effect — neprilysin inhibition reduces BNP enzymatic degradation. Volume-depletion-mediated wall stress reduction from furosemide would be expected to lower BNP production, not raise it. Reducing furosemide to address the BNP rise misidentifies the mechanism and would be the wrong intervention.
14. A pharmacology student asks why sacubitril-valsartan, which inhibits neprilysin and thereby raises circulating levels of all natriuretic peptides including CNP (C-type natriuretic peptide), does not produce greater natriuresis and diuresis than would be expected from ANP and BNP elevation alone. The attending explains that this relates to fundamental receptor biology. Which of the following correctly explains why elevated CNP from neprilysin inhibition does not contribute to the natriuretic and diuretic effects that are central to sacubitril-valsartan's hemodynamic benefit?
A) CNP produces natriuresis through NPR-C receptors in the renal collecting duct; because neprilysin inhibition raises CNP only modestly compared to ANP and BNP, the absolute increase in NPR-C-mediated collecting duct sodium excretion is too small to be clinically detectable, even though the receptor and effector mechanisms are intact
B) CNP signals through NPR-B receptors rather than NPR-A; NPR-B is expressed predominantly in vascular endothelial cells, vascular smooth muscle, and chondrocytes — not in the renal collecting duct at functionally relevant levels; CNP's effects are therefore primarily vascular (vasodilation and antiproliferation) and do not include the natriuretic and diuretic actions mediated by ANP and BNP acting through NPR-A in the kidney; elevated CNP from neprilysin inhibition increases vascular effects but not natriuresis
C) CNP does produce natriuresis through NPR-A receptors, but its affinity for NPR-A is approximately 1000-fold lower than that of ANP; the absolute increase in CNP from neprilysin inhibition is therefore insufficient to meaningfully activate NPR-A above baseline even though ANP and BNP at the same elevated concentrations produce full receptor occupancy
D) CNP is not a substrate for neprilysin; its plasma concentrations are therefore unaffected by sacubitril, and the absence of CNP elevation explains why the natriuretic response to sacubitril-valsartan is limited to the contributions of elevated ANP and BNP alone
E) CNP produces natriuresis only in the setting of acute volume expansion from intravenous saline; in the chronic compensated volume state of outpatient HFrEF management, CNP receptors in the collecting duct are downregulated by chronic sodium retention and do not respond to elevated CNP concentrations regardless of their source
ANSWER: B
Rationale:
Option B is correct. The three natriuretic peptides signal through distinct receptor subtypes that are expressed in different tissues and mediate different physiological actions. ANP and BNP both act through NPR-A (natriuretic peptide receptor A), a transmembrane receptor with intrinsic guanylyl cyclase activity expressed in renal collecting duct cells, vascular smooth muscle, adrenal zona glomerulosa, and juxtaglomerular cells; NPR-A activation generates cGMP and mediates natriuresis, diuresis, vasodilation, aldosterone suppression, and renin suppression. CNP, by contrast, acts through NPR-B (natriuretic peptide receptor B), also a guanylyl cyclase receptor, but one expressed predominantly in vascular endothelial cells, vascular smooth muscle cells, and chondrocytes. The renal tubule expresses NPR-B at levels too low to mediate clinically relevant natriuresis. As a result, CNP's principal actions are local vasodilation and inhibition of vascular smooth muscle proliferation — not systemic natriuresis or diuresis. When sacubitril inhibits neprilysin and raises CNP concentrations, the elevated CNP cannot replicate the natriuretic effects of elevated ANP and BNP because it lacks access to functionally relevant NPR-B in the renal tubule. The natriuretic and diuretic benefits of sacubitril-valsartan derive from elevated ANP and BNP acting on renal NPR-A.
Option A: Option A is incorrect. CNP does not produce natriuresis through NPR-C receptors; NPR-C is the natriuretic peptide clearance receptor linked to inhibitory adenylyl cyclase signaling, not a mediator of natriuresis. CNP's primary signaling receptor is NPR-B, not NPR-C, and neither NPR-C nor NPR-B mediates the renal tubular natriuretic response that is central to natriuretic peptide pharmacology.
Option C: Option C is incorrect. CNP's lack of natriuretic effect is not attributable to low NPR-A affinity; CNP has substantially lower affinity for NPR-A compared to ANP and BNP, but the fundamental distinction is receptor subtype: CNP preferentially signals through NPR-B, not NPR-A, and NPR-B is not the natriuretic receptor in the kidney. Even if CNP concentrations were substantially higher, its preferred receptor (NPR-B) is not expressed at functionally relevant levels in the renal collecting duct.
Option D: Option D is incorrect. CNP is in fact a substrate for neprilysin; neprilysin cleaves CNP along with ANP, BNP, bradykinin, and other vasoactive peptides. Sacubitril does raise CNP levels through neprilysin inhibition. The reason CNP elevation does not contribute to natriuresis is receptor biology — NPR-B rather than NPR-A — not substrate status.
Option E: Option E is incorrect. CNP receptor expression and responsiveness in the collecting duct are not the basis for the absence of CNP natriuresis. The relevant collecting duct receptor for natriuresis is NPR-A, which responds to ANP and BNP; CNP acts through NPR-B, which is not the renal tubular natriuretic receptor. The explanation invoking chronic collecting duct downregulation is not established physiology and does not address the fundamental receptor subtype distinction.
15. A 77-year-old man with HFrEF (ejection fraction 27%), NYHA class II-III symptoms, and advanced CKD (eGFR 22 mL/min/1.73 m²) has been managed on valsartan 80 mg twice daily and carvedilol 12.5 mg twice daily. His cardiologist considers upgrading to sacubitril-valsartan. The clinical pharmacist is asked to advise on whether the drug can be used in this patient and at what dose. Which of the following most accurately applies the pharmacokinetic basis for dose adjustment and the relevant clinical considerations?
A) Sacubitril-valsartan is contraindicated at eGFR below 30 mL/min/1.73 m²; the PARADIGM-HF trial excluded patients with eGFR below 30 mL/min/1.73 m², and no pharmacokinetic data exist to guide dosing in this range; the drug should not be prescribed until the patient's eGFR recovers above 30 mL/min/1.73 m²
B) No dose adjustment is required for either the sacubitril or valsartan component at any level of renal impairment; sacubitril is activated by plasma esterases unaffected by renal function, and both LBQ657 (the active sacubitril metabolite) and valsartan are primarily eliminated by biliary/fecal excretion rather than renal excretion
C) Dose adjustment is required for the valsartan component only; LBQ657 is eliminated by hepatic glucuronidation, which is unaffected by renal impairment; valsartan is renally cleared and accumulates in advanced CKD, requiring reduction to 26 mg per dose within the combination tablet
D) The sacubitril component requires dose adjustment but the valsartan component does not; LBQ657 is renally excreted and accumulates at eGFR below 30 mL/min/1.73 m², while valsartan is primarily eliminated by biliary/fecal excretion; sacubitril-valsartan should be initiated at sacubitril 24 mg / valsartan 103 mg, a dose that is not available as a fixed combination and requires compounding
E) LBQ657, the active neprilysin inhibitor generated from sacubitril, is eliminated primarily by renal excretion of unchanged drug; at eGFR of 22 mL/min/1.73 m², LBQ657 accumulates and the prescribing information specifies initiating at the lowest available dose of sacubitril 24 mg / valsartan 26 mg twice daily; the patient is eligible for the drug but requires lowest-dose initiation, close monitoring of blood pressure, renal function, and potassium, and gradual uptitration
ANSWER: E
Rationale:
Option E is correct. LBQ657 — the pharmacologically active neprilysin inhibitor generated from sacubitril by plasma esterase hydrolysis — has a plasma half-life of approximately 11 to 12 hours and is eliminated primarily by renal excretion of unchanged drug. In patients with significantly reduced GFR, LBQ657 clearance is impaired and systemic exposure increases. The sacubitril-valsartan prescribing information specifies initiating at the lowest available dose (sacubitril 24 mg / valsartan 26 mg twice daily) when eGFR falls below 30 mL/min/1.73 m², which applies to this patient with eGFR of 22 mL/min/1.73 m². Importantly, eGFR below 30 mL/min/1.73 m² does not constitute an absolute contraindication; pharmacokinetic studies and open-label registry data have been used to characterize exposure in this range since PARADIGM-HF excluded these patients. The drug can be used with lowest-dose initiation, close monitoring of blood pressure (vasodilatory effect from elevated natriuretic peptides plus AT1 blockade), renal function (creatinine threshold of 30% rise), and potassium (threshold for hold at 5.5 mEq/L), with slow uptitration guided by tolerance. The valsartan component is eliminated predominantly by biliary/fecal excretion (approximately 70%) and is less affected by renal impairment than LBQ657.
Option A: Option A is incorrect. eGFR below 30 mL/min/1.73 m² is not an absolute contraindication to sacubitril-valsartan; it is an indication for lowest-dose initiation and enhanced monitoring. The prescribing information addresses dosing in severe renal impairment and does not list eGFR below 30 mL/min/1.73 m² as a contraindication. Withholding a mortality-reducing therapy from an eligible HFrEF patient because he was not represented in the pivotal trial would deny the patient guideline-recommended care without a regulatory or pharmacokinetic basis for contraindication.
Option B: Option B is incorrect. LBQ657 is not eliminated by biliary/fecal excretion; it is eliminated primarily by renal excretion of unchanged drug. Renal impairment significantly affects LBQ657 clearance and is the pharmacokinetic basis for the dose adjustment requirement at eGFR below 30 mL/min/1.73 m². Valsartan is primarily eliminated by biliary/fecal excretion, which is accurately described, but the claim that no dose adjustment is required at any level of renal impairment for either component is incorrect for the sacubitril (LBQ657) component.
Option C: Option C is incorrect. LBQ657 is not eliminated by hepatic glucuronidation; it is renally excreted as unchanged drug. Hepatic glucuronidation is a Phase II metabolic pathway relevant to drugs such as morphine (morphine-6-glucuronide) and certain statins, but not to LBQ657. The valsartan component is not primarily renally cleared; it is predominantly eliminated by biliary/fecal excretion, making the option's mechanistic descriptions for both components inaccurate.
Option D: Option D is incorrect. Sacubitril-valsartan is manufactured as a fixed-dose combination tablet; the three available doses are sacubitril 24 mg / valsartan 26 mg, sacubitril 49 mg / valsartan 51 mg, and sacubitril 97 mg / valsartan 103 mg. A formulation containing sacubitril 24 mg with valsartan 103 mg does not exist as a commercial fixed-dose combination and cannot be prescribed as such; compounding is not the recommended clinical approach. The correct dose adjustment is to use the lowest available fixed-dose combination (sacubitril 24 mg / valsartan 26 mg) for the entire product, not to adjust only one component.
16. A 63-year-old man with HFrEF (ejection fraction 38%), NYHA class II symptoms, blood pressure 132/80 mmHg, eGFR 62 mL/min/1.73 m², and no history of angioedema has been tolerating enalapril 10 mg twice daily for two years. His primary care physician questions whether sacubitril-valsartan is indicated in a patient who is already doing well on enalapril, particularly since his ejection fraction is at the higher end of the HFrEF range. Which of the following most accurately applies the PARADIGM-HF subgroup data and guideline criteria to counsel this patient and physician?
A) Sacubitril-valsartan is indicated only for patients with ejection fraction at or below 30%; PARADIGM-HF demonstrated a statistically significant mortality benefit only in the severely reduced ejection fraction subgroup, and the overall trial result was driven by that subgroup; at an ejection fraction of 38%, the benefit is uncertain and the 2022 guidelines assign a Class IIb recommendation for this range
B) The primary care physician is correct that stable, asymptomatic patients on enalapril should not be transitioned to sacubitril-valsartan; PARADIGM-HF demonstrated benefit only in patients with NYHA class III-IV symptoms, and the NYHA class II subgroup did not achieve statistical significance for the primary endpoint; this patient's NYHA class II status means the evidence does not support substitution
C) Sacubitril-valsartan should be reserved for patients who have failed enalapril in the sense of having progressive symptoms or hospitalizations despite optimal ACEi dosing; a patient doing well on enalapril does not meet the failure criterion and transitioning him would expose him to the angioedema and hypotension risks of sacubitril-valsartan without the trial-defined benefit threshold being met
D) PARADIGM-HF enrolled patients with ejection fraction up to 40% (later amended to 35%) and NYHA class II-IV symptoms, and demonstrated consistent benefit across all prespecified subgroups including patients with ejection fraction in the 35-40% range and patients with NYHA class II symptoms; benefit was also consistent regardless of prior ACEi versus ARB use; this patient meets the guideline Class I, LOE A criteria for sacubitril-valsartan substitution, and doing well on enalapril is not a contraindication — it is evidence that he can tolerate RAAS blockade
E) Sacubitril-valsartan is recommended only when enalapril is dosed below the target of 10 mg twice daily; since this patient is already at target enalapril dose, the guideline algorithm does not proceed to ARNI substitution; the next step would be to optimize mineralocorticoid receptor antagonist therapy before considering ARNI
ANSWER: D
Rationale:
Option D is correct. PARADIGM-HF enrolled patients with HFrEF defined as ejection fraction at or below 40% (subsequently protocol-amended to at or below 35%) and NYHA class II through IV symptoms. The trial demonstrated statistically significant and clinically meaningful reductions in the primary endpoint, cardiovascular mortality, and all-cause mortality that were consistent across all prespecified subgroups, including patients with ejection fraction in the 35-40% range, patients with NYHA class II symptoms (who constituted the majority of the trial population), and patients who had been on ACEi versus ARB prior to randomization. An ejection fraction of 38% at the time of enrollment places this patient within the originally enrolled range, and his NYHA class II status is the most common presentation in the trial. The fact that a patient is doing well on enalapril is not a criterion for withholding sacubitril-valsartan; PARADIGM-HF specifically enrolled stable patients tolerating RAAS-blocking therapy and demonstrated benefit in this exact population. Tolerating enalapril is, as noted, evidence that RAAS blockade is tolerated and that transition to sacubitril-valsartan with the 36-hour ACEi washout is feasible. The 2022 AHA/ACC/HFSA guidelines assign Class I, LOE A to sacubitril-valsartan for symptomatic HFrEF patients who can tolerate RAAS blockade — this patient meets all criteria.
Option A: Option A is incorrect. PARADIGM-HF enrolled patients with ejection fraction up to 40% (later 35%) and demonstrated benefit across the enrolled ejection fraction range, not only in patients with ejection fraction at or below 30%. The 2022 guidelines assign Class I, LOE A — not Class IIb — for sacubitril-valsartan in symptomatic HFrEF, which includes patients with ejection fractions across the HFrEF range. No ejection fraction floor of 30% exists in the guideline recommendation.
Option B: Option B is incorrect. NYHA class II patients constituted the majority of PARADIGM-HF enrollees, and the trial was powered and demonstrated significant benefit in this subgroup. Restricting sacubitril-valsartan to NYHA class III-IV based on a subgroup analysis misrepresents the trial design and outcomes. The guideline indication includes NYHA class II through IV, and NYHA class II is specifically supported.
Option C: Option C is incorrect. There is no "failure criterion" for enalapril as a prerequisite for sacubitril-valsartan substitution in the guideline recommendation. The guideline calls for substituting sacubitril-valsartan for ACEi or ARB in symptomatic HFrEF patients who can tolerate RAAS blockade — not only in those who have failed ACEi therapy by progressive symptoms or hospitalizations. A patient doing well on enalapril with residual symptoms (NYHA class II) and reduced ejection fraction meets the substitution criteria.
Option E: Option E is incorrect. The guideline algorithm for sacubitril-valsartan substitution does not require enalapril to be below target dose as a prerequisite; enalapril at target dose of 10 mg twice daily is the ideal state for transitioning to sacubitril-valsartan, because it confirms ACEi tolerability. Mineralocorticoid receptor antagonist optimization is a parallel guideline mandate, not a prerequisite for ARNI initiation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.